Efficacy and safety of omalizumab (anti-IgE monoclinal antibody) on oral immunotherapy for patients with cow's milk allergy (randomized control study)
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Omalizumab (Primary)
- Indications Milk hypersensitivity
- Focus Therapeutic Use
- 16 Feb 2017 Status changed from active, no longer recruiting to completed.
- 06 May 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 05 Nov 2014 New trial record